摘要The heterogeneity of triple-negative breast cancer(TNBC)has spurred the exploration of precision therapies based on molecular subtypes,with the androgen receptor(AR)-positive subtype emerging as a potential therapeutic target.The treatment of AR-positive TNBC relies primarily on androgen receptor antagonists,such as enobosarm,bicalutamide,and enzalutamide.To enhance efficacy,researchers are investigating combination therapies that integrate anti-androgen agents with chemotherapy,immunotherapy,or PARP inhibitors.Additionally,studies have revealed that the AR signaling pathway regulates the tumor microenvironment,and AR inhibition may potentiate the efficacy of immune checkpoint inhibitors.However,anti-AR therapies face significant limitations and challenges due to multifaceted factors,necessitating further resolution.With continued advancements,AR-targeted therapy holds promise as a critical component of personalized treat-ment strategies for TNBC.